糖皮质激素性骨质疏松症的生物靶向药物治疗研究进展

doi:10.12114/j.issn.1007-9572.2021.02.071

中国全科医学 ›› 2022, Vol. 25 ›› Issue (06): 756-759.DOI: 10.12114/j.issn.1007-9572.2021.02.071

所属专题：骨质疏松最新文章合集；骨健康最新文章合集；安全用药最新文章合集

糖皮质激素性骨质疏松症的生物靶向药物治疗研究进展

胡忠慧1,2, 张茜1, 李梅1,^*

1．100730　北京市，中国医学科学院　北京协和医院内分泌科　国家卫生和健康委员会内分泌重点实验室
2．300450　天津市，北京大学滨海医院（天津市第五中心医院）内分泌科

收稿日期:2021-08-04 修回日期:2021-09-22 出版日期:2022-02-20 发布日期:2022-01-25
通讯作者: 李梅
基金资助:
国家自然科学基金面上项目(81873668，82070908);北京市自然科学基金资助项目(7202153);国家重点研发计划(2018YFA0800801)

New Developments in Biotargeted Drug Therapies for Glucocorticoid-induced Osteoporosis

HU Zhonghui1，2，ZHANG Qian1，LI Mei1*

1.Department of Endocrinology，Chinese Academy of Medical Sciences & Peking Union Medical College Hospital/ Key Laboratory of Endocrinology，National Health Commission of the People's Republic of China，Beijing 100730，China
2.Department of Endocrinology，Peking University Binhai Hospital（Tianjin Fifth Central Hospital），Tianjin 300450，China
*Corresponding author：LI Mei，Professor，Chief physician；E-mail：limeilzh@sina.com

Received:2021-08-04 Revised:2021-09-22 Published:2022-02-20 Online:2022-01-25

分享到

摘要/Abstract

摘要： 糖皮质激素性骨质疏松症（GIOP）是最常见的继发性骨质疏松，但未被充分重视，其治疗极具挑战性。核因子-κB受体活化因子配体（RANKL）介导的破骨细胞激活、Wnt信号通路抑制引发的骨形成减少是GIOP的重要发病机制，针对此病理机制的生物靶向抗骨质疏松治疗研究已取得长足进展。本文总结了生物靶向药物——地舒单抗、硬骨抑素单抗、Dickkopf-1单抗（DKK-1单抗）治疗GIOP的研究结果，发现地舒单抗能够显著增加GIOP患者骨密度，硬骨抑素单抗和DKK-1单抗有望成为GIOP的新型治疗药物。但目前上述生物靶向药物的临床研究有限，有待进一步开展。

关键词: 骨质疏松, 糖皮质激素性骨质疏松症, 地舒单抗, 硬骨抑素, DKK-1, 单克隆抗体

Abstract:

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, but its treatment is challenging, which may be due to lack of focus. Recent years have seen considerable developments in biotargeted therapies targeting two important pathophysiologic mechanisms for treating GIOP, including increased osteoclast activities induced by receptor activator of nuclear factor-κB ligand and decreased bone formation induced by inhibition of Wnt signaling pathway. We summarized the latest advances in three biotargeted drugs, denosumab, sclerostin monoclonal antibody and DKK-1 monoclonal antibody, in the treatment of GIOP, and found that denosumab can significantly increase bone mineral density of patients with GIOP, and sclerostin monoclonal antibody and DKK-1 monoclonal antibody are new promising therapies for GIOP. However, due to limited evidence, efficacies of these biotargeted drugs in GIOP need to be studied further.

Key words: Osteoporosis, Glucocorticoid-induced osteoporosis, Denosumab, Sclerostin, Dickkopf-1, Monocolonal antibody

中图分类号:

R681

胡忠慧,张茜,李梅. 糖皮质激素性骨质疏松症的生物靶向药物治疗研究进展[J]. 中国全科医学, 2022, 25(06): 756-759. DOI: 10.12114/j.issn.1007-9572.2021.02.071.

HU Zhonghui, ZHANG Qian, LI Mei.

New Developments in Biotargeted Drug Therapies for Glucocorticoid-induced Osteoporosis [J]. Chinese General Practice, 2022, 25(06): 756-759.

参考文献 40

[1]	FARDET L, PETERSEN I, NAZARETH I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years[J]. Rheumatology（Oxford），2011，50(11)：1982-1990. DOI：10.1093/rheumatology/ker017.
[2]	OVERMAN R A, YEH J Y, DEAL C L. Prevalence of oral glucocorticoid usage in the United States：a general population perspective[J]. Arthritis Care Res（Hoboken），2013，65(2)：294-298. DOI：10.1002/acr.21796.
[3]	LOCASCIO V, BONUCCI E, IMBIMBO B，et al. Bone loss in response to long-term glucocorticoid therapy[J]. Bone Miner，1990，8(1)：39-51. DOI：10.1016/0169-6009(91)90139-Q.
[4]	张学武，姚海红，梅轶芳，等. 全国多中心使用糖皮质激素风湿病患者骨质疏松调查[J]. 中华临床免疫和变态反应杂志，2017，11(3)：277-284. DOI：10.3969/j.issn.1673-8705.2017.03.014.
[5]	DING L L, HU J X, WANG D H，et al. Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures network meta-analysis[J]. J Clin Endocrinol Metab，2020，105(3)：600-613. DOI：10.1210/clinem/dgz023.
[6]	PEREIRA R M R, PEREZ M O, PAULA A P，et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis：an update of Brazilian Society of Rheumatology（2020）[J]. Arch Osteoporos，2021，16(1)：49. DOI：10.1007/s11657-021-00902-z.
[7]	中国医师协会风湿免疫科医师分会，中华医学会风湿病学分会，中华医学会骨质疏松和骨矿盐疾病分会，等. 2020版中国糖皮质激素性骨质疏松症防治专家共识[J]. 中华内科杂志，2021，60(1)：13-21. DOI：10.3760/cma.j.cn112138-20201102-00914.
[8]	CHOTIYARNWONG P, MCCLOSKEY E V. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment[J]. Nat Rev Endocrinol，2020，16(8)：437-447. DOI：10.1038/s41574-020-0341-0.
[9]	COMPSTON J. Glucocorticoid-induced osteoporosis：an update[J]. Endocrine，2018，61(1)：7-16. DOI：10.1007/s12020-018-1588-2.
[10]	BUCKLEY L, HUMPHREY M B. Glucocorticoid-induced osteoporosis[J]. N Engl J Med，2018，379(26)：2547-2556. DOI：10.1056/nejmcp1800214.
[11]	CHIODINI I, FALCHETTI A, MERLOTTI D，et al. Updates in epidemiology，pathophysiology and management strategies of glucocorticoid-induced osteoporosis[J]. Expert Rev Endocrinol Metab，2020，15(4)：283-298. DOI：10.1080/17446651.2020.1772051.
[12]	MATSUMOTO T, ENDO I. RANKL as a target for the treatment of osteoporosis[J]. J Bone Miner Metab，2021，39(1)：91-105. DOI：10.1007/s00774-020-01153-7.
[13]	ISERI K, IYODA M, WATANABE M，et al. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease：a randomized，controlled trial[J]. PLoS One，2018，13(3)：e0193846. DOI：10.1371/journal.pone.0193846.
[14]	HIROOKA Y, NOZAKI Y, INOUE A，et al. Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment[J]. Bone Rep，2020，13：100293. DOI：10.1016/j.bonr.2020.100293.
[15]	SAAG K G, WAGMAN R B, GEUSENS P，et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis：a multicentre，randomised，double-blind，active-controlled，double-dummy，non-inferiority study[J]. Lancet Diabetes Endocrinol，2018，6(6)：445-454. DOI：10.1016/S2213-8587(18)30075-5.
[16]	SAAG K G, PANNACCIULLI N, GEUSENS P，et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis：final results of a twenty-four-month randomized，double-blind，double-dummy trial[J]. Arthritis Rheumatol，2019，71(7)：1174-1184. DOI：10.1002/art.40874.
[17]	MATSUNO H. Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab，including those with rheumatoid arthritis and those receiving oral glucocorticoids[J]. DRUGS R D，2016，16(4)：347-353. DOI：10.1007/S40268-016-0146-8.
[18]	YANBEIY Z A, HANSEN K E. Denosumab in the treatment of glucocorticoid-induced osteoporosis：a systematic review and meta-analysis[J]. Drug Des Devel Ther，2019，13：2843-2852. DOI：10.2147/DDDT.S148654.
[19]	RAUNER M, TAIPALEENMÄKI H, TSOURDI E，et al. Osteoporosis treatment with anti-sclerostin antibodies-mechanisms of action and clinical application[J]. J Clin Med，2021，10(4)：787. DOI：10.3390/jcm10040787.
[20]	孟迅吾，周学瀛. 协和代谢性骨病学[M]. 北京：中国协和医科大学出版社，2021：542-557.
[21]	WIJENAYAKA A R, KOGAWA M, LIM H P，et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway[J]. PLoS One，2011，6(10)：e25900. DOI：10.1371/journal.pone.0025900.
[22]	VAN LIEROP A H, APPELMAN-DIJKSTRA N M, PAPAPOULOS S E. Sclerostin deficiency in humans[J]. Bone，2017，96：51-62. DOI：10.1016/J.BONE.2016.10.010.
[23]	VAN LIEROP A H, HAMDY N A, PAPAPOULOS S E. Glucocorticoids are not always deleterious for bone[J]. J Bone Miner Res，2010，25(12)：2796-2800. DOI：10.1002/JBMR.151.
[24]	SATO A Y, CREGOR M, DELGADO-CALLE J，et al. Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of sost/sclerostin[J]. J Bone Miner Res，2016，31(10)：1791-1802. DOI：10.1002/JBMR.2869.
[25]	YAO W, DAI W, JIANG L，et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength[J]. Osteoporos Int，2016，27(1)：283-294. DOI：10.1007/S00198-015-3308-6.
[26]	ACHIOU Z, TOUMI H, TOUVIER J，et al. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia[J]. Bone，2015，81：691-701. DOI：10.1016/J.BONE.2015.09.010.
[27]	MARENZANA M, GREENSLADE K, EDDLESTON A，et al. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone[J]. Arthritis Rheum，2011，63(8)：2385-2395. DOI：10.1002/ART.30385.
[28]	IOLASCON G, MORETTI A, TORO G，et al. Pharmacological therapy of osteoporosis：what's new?[J]. Clin Interv Aging，2020，15：485-491. DOI：10.2147/CIA.S242038.
[29]	MARKHAM A. Romosozumab：first global approval[J]. Drugs，2019，79(4)：471-476. DOI：10.1007/s40265-019-01072-6.
[30]	DAVIS K, DAVENPORT K, SCHOTS L. FDA Approves EVENITYTM（romosozumab-aqqg） for the treatment of osteoporosis in postmenopausal women at high risk for fracture[EB/OL]. [2021-07-20]. .
[31]	JASCHKE N, HOFBAUER L C, GÖBEL A，et al. Evolving functions of Dickkopf-1 in cancer and immunity[J]. Cancer Lett，2020，482：1-7. DOI：10.1016/J.CANLET.2020.03.031.
[32]	RACHNER T D, GOBEL A, BENAD-MEHNER P，et al. Dickkopf-1 as a mediator and novel target in malignant bone disease[J]. Cancer Lett，2014，346：172-177. DOI：10.1016/j.canlet.2014.01.010.
[33]	HEILAND G R, ZWERINA K, BAUM W，et al. Neutralisation of DKK-1 protects from systemic bone loss during inflammation and reduces sclerostin expression[J]. Ann Rheum Dis，2010，69(12)：2152-2159. DOI：10.1136/ard.2010.132852.
[34]	TAI N, INOUE D. Anti-Dickkopf1（DKK1） antibody as a bone anabolic agent for the treatment of osteoporosis[J]. Clin Calcium，2014，24(1)：75-83.
[35]	GLANTSCHNIG H, SCOTT K, HAMPTON R，et al. A rate-limiting role for Dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody[J]. J Pharmacol Exp Ther，2011，338(2)：568-578. DOI：10.1124/jpet.111.181404.
[36]	LIU M, KURIMOTO P, ZHANG J，et al. Sclerostin and DKK1 inhibition preserves and augments alveolar bone volume and architecture in rats with alveolar bone loss[J]. J Dent Res，2018，97(9)：1031-1038. DOI：10.1177/0022034518766874.
[37]	FLORIO M, GUNASEKARAN K, STOLINA M，et al. A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair[J]. Nat Commun，2016，7：11505. DOI：10.1038/ncomms11505.
[38]	IYER S P, BECK J T, STEWART A K，et al. A PhaseⅠB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events[J]. Br J Haematol，2014，167(3)：366-375. DOI：10.1111/bjh.13056.
[39]	KATO T, KHANH V C, SATO K，et al. Elevated expression of DKK-1 by glucocorticoid treatment impairs bone regenerative capacity of adipose tissue-derived mesenchymal stem cells[J]. Stem Cells Dev，2018，27(2)：85-99. DOI：10.1089/scd.2017.0199.
[40]	COLDITZ J, THIELE S, BASCHANT U，et al. Osteogenic DKK1 mediates glucocorticoid-induced but not arthritis-induced bone loss[J]. J Bone Miner Res，2019，34(7)：1314-1323. DOI：10.1002/JBMR.3702.

糖皮质激素性骨质疏松症的生物靶向药物治疗研究进展

New Developments in Biotargeted Drug Therapies for Glucocorticoid-induced Osteoporosis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

编辑推荐

Metrics

留言

[1]	曾令烽, 杨伟毅, 梁桂洪, 肖萧, 罗明辉, 潘建科, 韩燕鸿, 黄和涛, 赵金龙, 徐南俊, 周光辉, 张献泉, 梁伟雄, 欧爱华, 刘军, 广东省中医药学会骨关节退变与损伤专业委员会. 骨质疏松高危人群中医症状评估专家问卷调查和结果研究[J]. 中国全科医学, 2023, 26(24): 2986-2991.
[2]	孟凡, 董敏洁, 郭瑾, 许松涛, 严薇, 顾俊, 陈忆蓉, 杨乘, 王军, 夏丽芳, 陈俊, 富灵杰. 社区老年人骨质疏松患病情况及全科防控策略[J]. 中国全科医学, 2023, 26(22): 2778-2784.
[3]	许海娜, 安苗苗, 朱焱, 吴春艳, 冉利梅. 围绝经期体检女性肌肉和脂肪组织与骨密度的关系研究[J]. 中国全科医学, 2023, 26(21): 2626-2631.
[4]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南（2022）[J]. 中国全科医学, 2023, 26(14): 1671-1691.
[5]	王茜茜, 沈睿, 王俊杰, 徐霓影. 绝经后骨质疏松症患者运动干预的最佳证据总结[J]. 中国全科医学, 2023, 26(09): 1151-1158.
[6]	林燕平, 郭海威, 黄佳纯, 袁嘉尧, 林贤灿, 万雷, 黄宏兴. 骨质疏松症与肌-骨-脂关系研究[J]. 中国全科医学, 2023, 26(09): 1080-1085.
[7]	李仕田, 吕晓港, 朱晓祺, 王嘉烨, 卢晓翠. 久坐行为及运动水平对大学生跟骨骨密度的影响研究[J]. 中国全科医学, 2023, 26(06): 725-733.
[8]	嵇星辰, 王明欣, 陈少华, 高改, 吴小婉. 中国绝经后2型糖尿病患者骨质疏松影响因素的Meta分析[J]. 中国全科医学, 2023, 26(04): 504-511.
[9]	章轶立, 黄馨懿, 齐保玉, 孙传睿, 王晓阳, 魏戌, 谢雁鸣. 老年人群共病问题现状挑战与应对策略[J]. 中国全科医学, 2022, 25(35): 4363-4368.
[10]	韩涛, 孙凯, 孙传睿, 章轶立, 谢雁鸣, 申浩, 王旭, 齐保玉, 朱立国, 魏戌. 骨质疏松症与腰椎间盘突出症共病调查及影响因素分析[J]. 中国全科医学, 2022, 25(35): 4375-4380,F01.
[11]	魏戌, 刘宁, 章轶立, 韩涛, 孙凯, 齐保玉, 陈忻, 秦晓宽, 高景华, 谢雁鸣, 朱立国. 骨质疏松症的共病研究与早期筛查[J]. 中国全科医学, 2022, 25(35): 4369-4374.
[12]	王淑芳, 王秀艳, 闫玉伟, 娜日苏, 衡玉钰, 吴汝虹, 金玲, 安娟, 梅艳, 邬晓春, 刘贞庆. 老年男性发生骨质疏松的影响因素及其健康体适能情况研究[J]. 中国全科医学, 2022, 25(18): 2188-2193.
[13]	戴靖榕, 李婕, 何旭, 李杨, 李燕. 慢性疾病稳定期老年患者发生骨质疏松症的影响因素研究[J]. 中国全科医学, 2022, 25(18): 2194-2200.
[14]	倪会芳, 李隽, 丁源, 付群, 吴文迅. 中性粒细胞/淋巴细胞比值和单核细胞/高密度脂蛋白胆固醇比值预测绝经后2型糖尿病患者发生骨质疏松症的价值研究[J]. 中国全科医学, 2022, 25(18): 2207-2214.
[15]	孙传睿, 章轶立, 齐保玉, 方圣杰, 韩涛, 谢雁鸣, 魏戌, 朱立国. 社区绝经后骨质疏松症患者中医体质分布规律及阳虚质影响因素研究[J]. 中国全科医学, 2022, 25(18): 2201-2206.